IMAXIO was formed in 2006 by the merger of Diagnogene and Avidis (a spin-off developed in 2000 by the Medical Research Council and the University of Cambridge in the UK).

IMAXIO is an integrated biotech company focused on vaccines and genomics, and based on the combination of R&D and commercial activities:

PHARMACEUTICAL PRODUCTS: a vaccine against human leptospirosis and an orphan drug indicated in Wilson disease, both of them marketed in France.

IMX313 TECHNOLOGY PLATFORM: an immunoenhancing antigen re-engineering platform for vaccines and immunotherapies development.

GENOMICS PLATFORM: a R&D and services platform in genomics for the development of companion diagnostic tests in immunology and oncology.

Its development is based on the growth of its products and services revenues, as well as on acquisition of synergistic products and technologies, to sustain R&D programs.

In 2012, IMAXIO has a turnover of € 2.7 Million. It wants to strengthen it over the next 3 years with the acquisition of 2 or 3 pharmaceutical products already marketed in France or in Europe. Finally, in order to pursue the development of its proprietary technology IMX313, IMAXIO is seeking partners, and is looking in particular for laboratories which have know-how on antigens with a lack of immunogenicity.